References
- McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998; 57(6): 350–6
- Fuchs HA, Kaye JJ, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16(5): S85–91
- van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995; 22(9): 1792–6
- Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46(2): 347–56
- Porter DR, Grigor C, Stirling A, et al. A randomised controlled trial of a strategy of tight control of disease activity in rheumatoid arthritis—outcome over 18 months. (Abstr 515) Arthritis Rheum 2003; 48(Supp1): S232
- Breedveld FC, Rau R, van Riel PL, et al. Sustained efficacy over 5 years with adalimumab (Humira) in patients with active rheumatoid arthritis. (Abstr 198) Arthritis Rheum 2003; 48(Supp1): S118
- Kremer JM, Weinblatt ME, Fleischmann RM, et al. Etanercept (Enbrel) added to background methotrexate in rheumatoid arthritis: continued observations. (Abstr 1421) Arthritis Rheum 2002; 46(Supp1): S531
- Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Eng J Med 2000; 343(22): 1594–602
- Lipsky P, van der Heijde D, St Clair W, et al. 102-week clinical and radiologic results from the ATTRACT trial: a 2-year, randomized, controlled phase 3 trial of infliximab (Remicade) in patients with active rheumatoid arthritis despite methotrexate. (Abstr 1216) Arthritis Rheum 2000; 43(Supp1): S269
- Chartash E, Vasey F, Yount S, et al. Adalimumab improves fatigue in patients with active rheumatoid arthritis. (Abstr SAT0225) Ann Rheum Dis 2003; 62(Supp1): 349
- Smolen JS, Emery P, Bathon J, et al. Treatment of early rheumatoid arthritis with infliximab plus methotrexate or methotrexate alone: preliminary results of the ASPIRE trial. (Abstr OP000l) Presented at the Annual European Congress of Rheumatology, Jun 2003, Lisbon
- Klareskog L, van der Heijde D, de Jager JP, et al; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363(9410): 675–81
- Antoni C, Kavanaugh A, Kirkham B, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). (Abstr 985) Arthritis Rheum 2002; 46(Supp1): S381
- Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357(9271): 1842–7
- Chen DM, Gordon K, Leonardi C, et al. Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary findings from a 12-week dose-ranging trial. J Am Acad Dermatol 2004; 50(3 Pt 2): P1
- Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50(7): 2264–72
- Ory P, Sharp JT, Salonen D, et al. Etanercept (Enbrel) inhibits radiographic progression in patients with psoriatic arthritis. (Abstr 442) Arthritis Rheum 2002; 46(Supp1): S196
- Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359(9313): 1187–93
- Davis JC Jr, van der Heijde D, Braun J, et al; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48(11): 3230–6
- Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346(18): 1349–56